Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Gria2em1/Cya
Common Name:
Gria2-KO
Product ID:
S-KO-02333
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Gria2-KO
Strain ID
KOCMP-14800-Gria2-B6J-VA
Gene Name
Gria2
Product ID
S-KO-02333
Gene Alias
GluA2; GluR-B; Glur-2; Glur2; gluR-K2
Background
C57BL/6JCya
NCBI ID
14800
Modification
Conventional knockout
Chromosome
3
Phenotype
MGI:95809
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Gria2em1/Cya mice (Catalog S-KO-02333) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000075316
NCBI RefSeq
NM_013540
Target Region
Exon 4
Size of Effective Region
~0.2 kb
Detailed Document
Click here to download >>
Overview of Gene Research
GRIA2, also known as Glutamate receptor, ionotropic, AMPA2 (alpha 2), encodes the GluA2 subunit of AMPA receptors (AMPARs). AMPARs are tetrameric ligand-gated channels, and GluA2 is crucial as post-transcriptional editing at the Q607 site makes heteromultimeric AMPARs Ca2+-impermeable, influencing current-voltage relationships. This gene is involved in glutamatergic synaptic transmission, which is vital for normal neural function [2].

In the context of diseases, GRIA2 has been implicated in multiple conditions. In lower extremity artery restenosis post-percutaneous transluminal angioplasty (PTA), GRIA2 is highly differentially expressed in restenotic arterial plaques. Its overexpression promotes the proliferation and migration of vascular smooth muscle cells (VSMCs) through upregulation of ENPP3, suggesting its role in the restenosis mechanism [1]. In neurodevelopmental disorders, heterozygous de novo GRIA2 mutations in patients can lead to intellectual disability (ID), autism spectrum disorder (ASD), Rett syndrome-like features, and seizures or developmental epileptic encephalopathy (DEE). Functional expression studies show that these mutations decrease agonist-evoked current mediated by mutant subunits [2]. A novel de novo missense mutation in a patient with epilepsy, developmental delay, and failure to thrive led to a gain-of-function in GluA2-containing AMPARs, and the antiseizure drug perampanel was effective in treating the patient [4]. Also, a de novo missense variant in GRIA2 was found in a patient with epileptic encephalopathy, autism spectrum disorder, and global developmental delay [6]. In methamphetamine-use disorder, serum GRIA2 is higher in patients, and miR-181a acts as a negative regulator of GRIA2 [5]. Moreover, GRIA2 is a useful diagnostic marker for solitary fibrous tumour, with high expression in a large proportion of these tumours [3].

In conclusion, GRIA2 is essential for normal neural function through its role in glutamatergic synaptic transmission. Its dysregulation is associated with various diseases, including lower extremity artery restenosis, neurodevelopmental disorders, and methamphetamine-use disorder. The study of GRIA2 in these disease models helps in understanding the disease mechanisms and potentially developing new treatment strategies.

References:

1. Zhou, Mi, Qi, Lixing, Gu, Yongquan. 2021. GRIA2/ENPP3 Regulates the Proliferation and Migration of Vascular Smooth Muscle Cells in the Restenosis Process Post-PTA in Lower Extremity Arteries. In Frontiers in physiology, 12, 712400. doi:10.3389/fphys.2021.712400. https://pubmed.ncbi.nlm.nih.gov/34504438/

2. Salpietro, Vincenzo, Dixon, Christine L, Guo, Hui, Kullmann, Dimitri M, Houlden, Henry. 2019. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. In Nature communications, 10, 3094. doi:10.1038/s41467-019-10910-w. https://pubmed.ncbi.nlm.nih.gov/31300657/

3. Vivero, Marina, Doyle, Leona A, Fletcher, Christopher D M, Mertens, Fredrik, Hornick, Jason L. 2014. GRIA2 is a novel diagnostic marker for solitary fibrous tumour identified through gene expression profiling. In Histopathology, 65, 71-80. doi:10.1111/his.12377. https://pubmed.ncbi.nlm.nih.gov/24456377/

4. Coombs, Ian D, Ziobro, Julie, Krotov, Volodymyr, Cull-Candy, Stuart G, Farrant, Mark. 2022. A gain-of-function GRIA2 variant associated with neurodevelopmental delay and seizures: Functional characterization and targeted treatment. In Epilepsia, 63, e156-e163. doi:10.1111/epi.17419. https://pubmed.ncbi.nlm.nih.gov/36161652/

5. Zhang, Kai, Wang, Qingzhong, Jing, Xuxiu, Yu, Shunying, Zhao, Min. 2016. miR-181a is a negative regulator of GRIA2 in methamphetamine-use disorder. In Scientific reports, 6, 35691. doi:10.1038/srep35691. https://pubmed.ncbi.nlm.nih.gov/27767084/

6. Latsko, Maeson S, Koboldt, Daniel C, Franklin, Samuel J, White, Peter, Wilson, Richard K. 2022. De novo missense mutation in GRIA2 in a patient with global developmental delay, autism spectrum disorder, and epileptic encephalopathy. In Cold Spring Harbor molecular case studies, 8, . doi:10.1101/mcs.a006172. https://pubmed.ncbi.nlm.nih.gov/35534222/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest